



semaglutide tablets (Wegovy®)

Novo Nordisk Ltd.

4 September 2026

ADVICE: in the absence of a submission from the holder of the marketing authorisation:

semaglutide tablet (Wegovy®) is not recommended for use within NHSScotland.

Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

- $\geq 30 \text{ kg/m}^2$ (obesity), or
- $\geq 27 \text{ kg/m}^2$ to $< 30 \text{ kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.

SMC has previously accepted semaglutide FlexTouch solution for injection in pre-filled pen (Wegovy®) for restricted use for this indication (SMC2497). This advice remains valid.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium